Compare AbCellera Biologics Inc (ABCL) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs T Rowe Price Group Inc — how do they compare? AbCellera Biologics Inc trades at $9.21 (market cap $2.99B), while T Rowe Price Group Inc trades at $116.99 (market cap $24.26B). The key difference: T Rowe Price Group Inc is far larger — about 8.1× AbCellera Biologics Inc's market cap, and T Rowe Price Group Inc pays a 4.57% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | TROW | |
|---|---|---|
Market Cap | $2.99B | $24.26B |
Sector | Health | Financials |
52-Week High | $9.76 | $121.68 |
52-Week Low | $2.78 | $86.19 |
Enterprise Value | $2.58B | $21.46B |
Dividend Yield | — | 4.57% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
